Related Experiment Video
Updated: Aug 25, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Nutraceutical-Based Nanoformulations for Breast and Ovarian Cancer Treatment
Simona Serini1,2, Roberta Cassano3, Federica Curcio3
1Department of Translational Medicine and Surgery, Section of General Pathology, School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito, 00168 Rome, Italy.
Abstract:
Different strategies have been investigated for a more satisfactory treatment of advanced breast cancer, including the adjuvant use of omega-3 polyunsaturated fatty acids (PUFAs). These nutritional compounds have been shown to possess potent anti-inflammatory and antiangiogenic activities, the capacity to affect transduction pathways/receptors involved in cell growth and to reprogram tumor microenvironment. Omega-3 PUFA-containing nanoformulations designed for drug delivery in breast cancer were shown to potentiate the effects of enclosed drugs, enhance drug delivery to target sites, and minimize drug-induced side effects. We have critically analyzed here the results of the most recent studies investigating the effects of omega-3 PUFA-containing nanoformulations in breast cancer. The anti-neoplastic efficacy of omega-3 PUFAs has also been convincingly demonstrated by using preclinical in vivo models of ovarian cancer. The results obtained are critically analyzed here and seem to provide a sufficient rationale to move to still lacking interventional clinical trials, as well as to evaluate possible advantages of enclosing omega-3 PUFAs to drug-delivery nanosystems for ovarian cancer. Future perspectives in this area are also provided.
Insights
Omega-3 polyunsaturated fatty acids (PUFAs) show promise in advanced breast and ovarian cancer treatments. Nanoformulations enhance PUFA delivery, boosting efficacy and reducing side effects, warranting clinical trials.
Area of Science:
- Oncology
- Nutritional Science
- Nanotechnology
Background:
- Advanced breast cancer treatment requires novel strategies.
- Omega-3 polyunsaturated fatty acids (PUFAs) exhibit anti-inflammatory and anti-angiogenic properties.
- PUFAs influence cell growth pathways and tumor microenvironment.
Purpose of the Study:
- To critically analyze recent studies on omega-3 PUFA-containing nanoformulations for breast cancer.
- To evaluate the anti-neoplastic efficacy of omega-3 PUFAs in ovarian cancer models.
- To explore the potential of omega-3 PUFAs in drug-delivery nanosystems for ovarian cancer.
Main Methods:
- Literature review of recent studies on omega-3 PUFA nanoformulations in breast cancer.
- Analysis of preclinical in vivo models for ovarian cancer treated with omega-3 PUFAs.
- Critical evaluation of existing data to identify research gaps and future directions.
Main Results:
- Omega-3 PUFA nanoformulations potentiate drug effects, improve target delivery, and minimize side effects in breast cancer.
- Preclinical models demonstrate significant anti-neoplastic efficacy of omega-3 PUFAs in ovarian cancer.
- Data suggests a strong rationale for clinical trials and exploring omega-3 PUFAs in ovarian cancer nanodrug delivery.
Conclusions:
- Omega-3 PUFA nanoformulations represent a promising strategy for advanced breast cancer treatment.
- Further research and clinical trials are warranted for omega-3 PUFAs in both breast and ovarian cancers.
- Integrating omega-3 PUFAs into nanodelivery systems could offer significant therapeutic advantages.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...